Analysts expect that Assembly Biosciences Inc (NASDAQ:ASMB) will announce $12.54 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Assembly Biosciences’ earnings, with estimates ranging from $4.00 million to $36.04 million. Assembly Biosciences posted sales of $3.08 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 307.1%. The business is scheduled to issue its next quarterly earnings results on Monday, August 3rd.
According to Zacks, analysts expect that Assembly Biosciences will report full year sales of $20.36 million for the current fiscal year, with estimates ranging from $10.21 million to $40.12 million. For the next financial year, analysts forecast that the company will post sales of $15.80 million, with estimates ranging from $14.00 million to $17.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.22. The business had revenue of $4.08 million during the quarter, compared to analysts’ expectations of $3.82 million. Assembly Biosciences had a negative net margin of 601.75% and a negative return on equity of 45.43%.
Assembly Biosciences stock traded up $0.65 during trading hours on Friday, hitting $23.81. The stock had a trading volume of 166,900 shares, compared to its average volume of 261,602. The company has a quick ratio of 12.14, a current ratio of 12.14 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $757.85 million, a P/E ratio of -6.94 and a beta of 1.26. Assembly Biosciences has a 12-month low of $8.13 and a 12-month high of $25.07. The stock’s 50-day moving average price is $20.86 and its 200-day moving average price is $18.82.
In other Assembly Biosciences news, EVP Richard James Colonno sold 7,812 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $15.04, for a total transaction of $117,492.48. Following the completion of the sale, the executive vice president now directly owns 144,821 shares of the company’s stock, valued at $2,178,107.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 12.42% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. State Street Corp increased its holdings in Assembly Biosciences by 18.4% during the first quarter. State Street Corp now owns 551,324 shares of the biopharmaceutical company’s stock valued at $8,176,000 after buying an additional 85,622 shares during the last quarter. Morgan Stanley increased its holdings in Assembly Biosciences by 169.2% during the first quarter. Morgan Stanley now owns 160,050 shares of the biopharmaceutical company’s stock valued at $2,374,000 after buying an additional 100,586 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Assembly Biosciences during the first quarter valued at approximately $175,000. Two Sigma Advisers LP boosted its position in shares of Assembly Biosciences by 1.6% in the first quarter. Two Sigma Advisers LP now owns 71,200 shares of the biopharmaceutical company’s stock worth $1,056,000 after purchasing an additional 1,100 shares during the period. Finally, Atom Investors LP bought a new position in shares of Assembly Biosciences in the first quarter worth approximately $2,002,000. 88.34% of the stock is owned by institutional investors and hedge funds.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Featured Story: Channel Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.